$63.49+0.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Company outlook: revenue of $1.3B to $1.3B for Fiscal year 2026 — down 24.6% on a year earlier ($1.7B)
Just reported
From PTC Therapeutics, Inc.'s results release of October 29, 2026; its quarterly report has since been filed.
Actual
$357.8M
+70% y/y
-0.8% q/q
Guided
—
No guide given
Actual
-$0.62
Guided
—
No guide given
Actual
$25.1M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $357.8M | $211M | +69.57% |
| Profit | -$51.7M | $15.9M | -425.20% |
| Profit per share | -$0.62 | $0.20 | -410.00% |
| Free Cash Flow | -$28M | -$69.8M | +59.94% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
PTC Therapeutics, Inc. has no earnings call transcript available.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company’s strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow on LinkedIn, X, Facebook and Instagram.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from PTC Therapeutics, Inc.’s Item 2.02 8-K filed October 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.